VISA and hVISA in hospitals
Iain B Gosbell
+ Author Affiliations
- Author Affiliations
A Ingham Institute for Applied Medical Research
Liverpool, NSW, Australia
B School of Medicine
University of Western Sydney
Penrith, NSW, Australia
C Department of Microbiology and Infectious Diseases
Sydney South West Pathology Service
Liverpool, NSW, Australia
Tel: +61 2 8738 9024
Fax: +61 2 9602 9441
Email: i.gosbell@uws.edu.au
Microbiology Australia 35(1) 29-34 https://doi.org/10.1071/MA14009
Published: 17 February 2014
Abstract
Staphylococcus aureus is noted for its clinical spectrum of disease ranging from asymptomatic colonisation to overwhelming sepsis and death and for its ability to become resistant to antibiotics. Resistance to beta-lactams, methicillin resistance, was first described 50 years ago, becoming a clinical problem in hospitals in the 1970s and the community in the 1990s. MRSA strains that originated in hospitals are usually also resistant to most of the non-beta-lactams as well, leaving vancomycin as the main parenteral drug to treat serious MRSA infections, with the role of new drugs like daptomycin and linezolid not well defined. MRSA strains can exhibit low-level resistance to vancomycin (vancomycin-intermediate S. aureus [VISA]), probably due to a thickened cell wall, which results in the trapping of vancomycin away from the active site of the septum in dividing cells. Detecting this resistance is difficult as multiple genetic pathways lead to this resistance, obviating a molecular test, forcing reliance on phenotypic tests, all of which have issues with sensitivity, specificity and cost. Mortality of bloodstream infection correlates with vancomycin MIC so in this situation the MIC should be determined by Etest or microbroth dilution especially if endocarditis is present. Detection of resistant subpopulations (heterogeneous vancomycin-intermediate S. aureus [hVISA]) can be done with the expensive and time-consuming population analysis profile (PAP) but it is unclear if this confers additional therapeutic information.
References
[1] Howden, B.P. et al. (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99–139.| Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXks1Sktb8%3D&md5=a6a17476112da9d497f3708c10668e7fCAS | 20065327PubMed |
[2] Perichon, B. and Courvalin, P. (2009) VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 4580–4587.
| VanA-type vancomycin-resistant Staphylococcus aureus.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXhtl2itLvF&md5=a133feef78b60620864ae466a5247101CAS | 19506057PubMed |
[3] Hiramatsu, K. et al. (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135–136.
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2sXltVCit7w%3D&md5=63fcf86212e15251f1ffb60f911f4eedCAS | 9249217PubMed |
[4] Hiramatsu, K. et al. (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670–1673.
| Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1cXns1em&md5=afcc9b21aa311ab1390f7cba53540786CAS | 9400512PubMed |
[5] Wootton, M. et al. (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47, 399–403.
| A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3MXjtVamtLk%3D&md5=9bca4e07bd879a074dfc727afed44116CAS | 11266410PubMed |
[6] Hiramatsu, K. (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1, 147–155.
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD38XltVOnsbs%3D&md5=378b6014be993f76c393af03b38d4559CAS | 11871491PubMed |
[7] Mwangi, M.M. et al. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 104, 9451–9456.
| Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXmtlegu7g%3D&md5=de43bb7acfd1cf49161977bd54fa0d10CAS | 17517606PubMed |
[8] Cameron, D.R. et al. (2012) Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J. Infect. Dis. 205, 1677–1687.
| Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xnt1amtLk%3D&md5=a9c35de4cb01beed690216d605c959aaCAS | 22492855PubMed |
[9] van Hal, S.J. et al. (2012) The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54, 755–771.
| The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XjtFKjtLg%3D&md5=ced5af9e0145acb453fb591f08b18c69CAS | 22302374PubMed |
[10] Holmes, N.E. et al. (2011) Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204, 340–347.
| Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXovVKqt7Y%3D&md5=173e41384998a38445f6a292e76f35bdCAS | 21742831PubMed |
[11] van Hal, S.J. and Paterson, D.L. (2011) Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55, 405–410.
| Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXisVegsLs%3D&md5=50acbb1098da587e2ea787e40512a049CAS | 21078939PubMed |
[12] Peleg, A.Y. et al. (2009) Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199, 532–536.
| Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection.Crossref | GoogleScholarGoogle Scholar | 19125671PubMed |
[13] van Hal, S.J. and Fowler, V.G. (2013) Is it time to replace vancomycin in the treatment of Methicillin-Resistant Staphylococcus aureus infections? Clin. Infect. Dis. 56, 1779–1788.
| Is it time to replace vancomycin in the treatment of Methicillin-Resistant Staphylococcus aureus infections?Crossref | GoogleScholarGoogle Scholar | 23511300PubMed |
[14] van Hal, S.J. et al. (2011) Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J. Clin. Microbiol. 49, 1489–1494.
| Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhtFKrt7fJ&md5=56d9e77e39da14d3220b9148c0761ceeCAS | 21270232PubMed |
[15] Holmes, N.E. et al. (2012) Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J. Clin. Microbiol. 50, 2548–2552.
| Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.Crossref | GoogleScholarGoogle Scholar | 22593595PubMed |
[16] van Hal, S.J. et al. (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient--a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30, 603–610.
| Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient--a review of the literature.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3MvivVyhug%3D%3D&md5=709e77c977c5ef577242570ca66c4d81CAS | 21191627PubMed |
[17] Sakoulas, G. et al. (2006) Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50, 1581–1585.
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XjvFOrtrc%3D&md5=55dfb7faf99b61c7e5a329ea5f84a54dCAS | 16569891PubMed |
[18] Patel, J.B. et al. (2006) An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42, 1652–1653.
| An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XlvVOrsrg%3D&md5=65e9bddf806607fa511204d6b26d0bdcCAS | 16652325PubMed |
